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Introduction: The evidence based data to guide management in patients of benzo-
diazepine refractory status epilepticus (SE) is still lacking. We conducted a rando-
mized study to evaluate the comparative effect of intravenous (IV) phenytoin and
intravenous valproate (IV VA) in patients of benzodiazepine refractory SE.
Background and methods: Hundred, age and sex matched, patients of benzodiaze-
pine refractory SE were randomly divided into Group A (50 patients), treated with IV
VA and Group B (50 patients) treated with IV phenytoin. Twelve patients, in whom SE
was not controlled with a single drug, were switched over to the other group.
Treatment was considered successful when all motor or EEG seizure activity ceased
within 20 min after the beginning of the drug infusion and no return of seizure activity
during the next 12 h. Secondary study end points were adverse events to treatment,
in-hospital complications and the neurological outcome at discharge.
Results: In this study, IV VAwas successful in 88% and IV phenytoin in 84% ( p > 0.05) of
patients of SE with a significantly better response in patients of SE <2 h ( p < 0.05).
The total number of adverse events did not differ significantly between the two
groups ( p > 0.05). There were no differences among the treatments with respect to
recurrence after 12-h study period or the outcome at 7 days.
Conclusion: IV VA is as effective as IV phenytoin. It is easy to use, better tolerated and
can be used as an alternative to IV phenytoin in patients of benzodiazepine refractory
SE, especially in patients of cardio-respiratory disease. The better outcome in
patients having shorter duration of SE (<2 h) suggests need of immediate treatment.
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Approximately 5% of adult and 10—25% of children
with epilepsy have at least one episode of status. Published by Elsevier Ltd. All rights reserved.
528 P. Agarwal et al.epilepticus (SE) during the course of their disease.1—3
SE is present in nearly all epileptic syndromes, even
idiopathic ones, although it is more frequent in cryp-
togenic and symptomatic forms.4 Phenobarbital,5—7
phenytoin,8—10 diazepam plus phenytoin11,12and lor-
azepam13—15 have been advocated for the initial
treatment of SE, and each is used by a substantial
numberof physicians. No randomizedcontrolleddata
supporting phenytoin as a second line treatment are
available, but one uncontrolled study suggested that
50% of patients not successfully treated with a ben-
zodiazepine alone would respond to a second line
treatment (usually phenytoin).16 Traditionally, based
on a long clinical experience, and case controlled
studies, intravenous (IV) phenytoin has been used as
the second drug.
Starting in the 1980s, the use of intravenous
valproate (IV VA) has been reported in an increasing
number of uncontrolled case series, indicating rela-
tive ease of use, relatively good tolerability and
suggesting that it may be efficacious.17 In one study,
20 adult patients in acute or static SE with general-
ized tonic—clonic seizures (GTCS) or simple partial
motor seizures were administered IV valproic acid in
a bolus dose of 15 mg/kg body weight and then as a
continuous infusion of 1 mg/kg/h for 24 h safely. SE
was interrupted in less than 30 min in 80% of cases.18
Recently, there are other reports about successful
use of IV VA in controlling SE19,20 but there is no
randomized comparative study to the best of our
knowledge till now. Hence, we planned a rando-
mized study to demonstrate the efficacy and safety
of IV VA as the initial therapy for controlling seizures
in patients of SE refractory to diazepam, and to
compare it with IV phenytoin.Materials and methods
This study was conducted on patients of status
epilepticus refractory to IV diazepam admitted in
emergency ward and intensive care unit from
December 2004 to February 2006. The definition
of SE is based on the clinical manifestations–—a
prolonged seizure or a series of seizures during
which the patient has incomplete recovery of con-
sciousness, and duration. The traditional definition
of status has been 30 min, however, the duration
parameter is highly controversial and has created a
flux in our definition of SE. The operational defini-
tion of SE proposed by Lowenstein et al.21 is a
continuous, generalized, convulsive seizure lasting
greater than 5 min, or two or more seizures during
which the patient does not return to baseline con-
sciousness. In our study patients of SE were defined
as continuous or repeated seizure activity for morethan 5 min without recovery of consciousness.22
Pregnant women, children less than 2 years of age
and patients of hepatic encephalopathy were
excluded from the study. Patients with myoclonic
status epilepticus, neurological emergency requir-
ing immediate surgical intervention, or contraindi-
cation to therapy with hydantoin, benzodiazepine,
or barbiturate drugs were also excluded. Only the
first episode was included in the analysis if the
patient was enrolled more than once by mistake.
The intention to treat analysis was done and
patients who left the treatment against medical
advice were also included in the study.
Out of 3000 patients of epilepsy seen in outdoor
and emergency ward, hundred patients were diag-
nosed as benzodiazepine resistant SE and included
for the study after taking informed consent from
conscious patients 18 years or from the parents in
case of unconscious patients and patients under 18
years of age. These patients were randomly divided
into groups A and B after matching for age and sex.
Fifty patients in Group A received IV valproic acid in
doses of 20 mg/kg (Limdi et al.20) as loading dose at
rate of 40 mg/min23—25 and 50 patients in Group B
received IV phenytoin in the doses of 20 mg/kg
(max. rate of 50 mg/min) after dilution with normal
saline. All these patients were earlier given IV dia-
zepam in doses of 0.2 mg/kg at 2 mg/min up to a
maximum of 20 mg before labeling as refractory to
diazepam.22 We used commercially available intra-
venous valproate (Encorate1, Sun Pharmaceuticals
Ind. Ltd., India).
Status epilepticus was considered to end at the
time when convulsive seizure ceased and the
patient subsequently regained consciousness. Sta-
tus epilepticus was considered ongoing when sei-
zures were clinically evident or when clinically
seizures ended but the patient remained comatose
and an electroencephalogram (EEG) indicated
ongoing electrical seizure activity, or when the
patient remained unconscious and subsequently
had a convulsive seizure requiring treatment with
an antiepileptic drug. We changed the therapy if
life-threatening seizures were continued as per the
standard protocol used in management of status
epilepticus. All patients were monitored for the
vitals viz. pulse, blood pressure, respiration, elec-
trocardiogram (ECG), seizure activity, Glasgow
coma scale (GCS), wherever required every 5 min
for 2 h, then every 15 min for 12 h. All patients were
followed for 7 days for seizure outcome and adverse
events. EEG was done in all patients and repeated
whenever required. Patients were followed up for 7
days to measure the outcome. All cases were inves-
tigated for complete blood count, blood sugar,
serum electrolytes, blood urea, serum creatinine
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Table 1 Etiology of status epilepticus





cases (n = 100)
1 Antiepileptic drug withdrawal/noncompliance 12 14 26
2 Inflammatory granuloma (NCCa/tuberculoma) 12 12 24
3 CNS infections 10 12 22
4 Primary generalized seizure 8 6 14
5 Cerebrovascular accidents 2 2 4
6 Exrtradural hematoma 2 0 2
7 JME 2 0 2
8 Brain metastasis 2 0 2
9 Chronic renal failure 0 2 2
10 Eclampsia 0 2 2
a NCC — neurocysticercosis.and liver enzymes. Cerebrospinal fluid examination
and computed tomography/magnetic resonance
imaging scans of brain to determine the etiology
of seizure were also performed.
Treatment was considered successful when all
motor or EEG seizure activity ceased within
20 min after the beginning of the drug infusion
and there was no return of seizure activity during
the next 12 h. Patients were switched over to the
other group if seizures were not controlled or recur-
rence present with in 12 h of the treatment. Sec-
ondary study end points were in-hospital
complications and neurological outcome at dis-
charge. The safety and efficacy of the two drugs
in each group were studied and the response was
compared between the two groups in terms of sig-
nificance using Student’s t test.Results
In the present studymean age of patients in Group A
was 27.4  16.8 years and Group B was 27  15.1
years. There were 35 (70%) males in Group A, 32
(64%) in Group B and 15 (30%) females in Group A
and 18 (36%) in Group B. There were 22 patients
below 18 years of age in Group A, and 16 patients in
Group B. The most common etiology of SE wasTable 2 Associated illnesses in patients of SE
S. no. Associated illnesses No. of cases
1 Septicemia 14
2 Pulmonary tuberculosis 6
3 Viral fever 8
4 CSOM 4
5 Diabetes mellitus 2
6 Cortical venous thrombosis 2
7 CA lung 2
8 Renal failure 2
9 None 60antiepileptic drug noncompliance or withdrawal
in 12 (24%) patients in Group A and 14 (28%) in
Group B, while the other etiologies included inflam-
matory granuloma [12 (24%) in Group A and 12 (24%)
in Group B], CNS infections [10 (20%) in Group A and
12 (24%) in Group B], primary generalized epilepsy
[8 (16%) in Group A and 6 (12%) in Group B], stroke [2
(4%) in Group A and 2 (4%) in Group B] and head
injury with exrtradural hematoma 2 (4%); in major-
ity of patients (Table 1). The illnesses associated
with SE (Table 2) were septicemia in 14 (14%)
patients, viral fever in 8 (8%) and pulmonary tuber-
culosis in 6 (6%). Other comorbid conditions
included chronic suppurative otitis media (CSOM),
diabetes mellitus and renal failure. In 60 cases
there was no significant associated illness. The
duration of SE at the time of presentation (Graph
1) was <2 h in 60% (30/50) in Group A and 52% (26/
50) in Group B. Interestingly, 40% (20/50) of Group A
and 48% (24/50) of Group B were admitted >3 h
after onset of SE. In these cases seizure activity had
seized to occur 30 min after the seizure onset, butGraph 1 Duration of status epilepticus.
530 P. Agarwal et al.
Table 3 Response to treatment in patients of status epilepticus
Response Group A (n = 50) Group B (n = 50)
No. of cases Percentage (%) No. of cases Percentage (%)
SE controlled 44 (n = 50) 88 * 42 (n = 50) 84 *
Not controlled 6 (n = 50) 12 8 (n = 50) 16
SE <2 h 30 (n = 30) 100 ** 25 (n = 26) 96y
SE >2 h 14 (n = 20) 70 ** 17 (n = 24) 71y
Treated with both drugs 4 (n = 7)z 57 2 (n = 5)z 40
* p > 0.05.
** p < 0.05.
y p < 0.05.
z p > 0.05.they failed to regain consciousness by the time of
hospital admission. In Group A, six cases were not
controlled on IV VA, of these one patient left against
medical advice and five cases were treated with IV
phenytoin out of which two were controlled. Eight
cases of Group B were not controlled with IV phe-
nytoin, out of which seven cases were treated with
IV VA, four cases were subsequently controlled and
three were refractory to both the study drugs
(Table 3). One patient left against medical advice
(Table 4). Thus, twelve patients of SE were common
in both groups and out of them six patients (50%)
were refractory to both the drugs.
IV VA was successful in 88% and IV phenytoin in
84% (p > 0.05) patients of SE (Table 3). There was
significant difference in response to treatment in
patients of SE <2 h and SE >2 h in Group A (100%
versus 70%) (p < 0.05) and Group B (96.15% versus
70.83%) (p < 0.05), respectively (Table 3). Among
patients <18 years of age, 20 of the 22 Group A
patients and 12 out of 16 Group B patients
responded to treatment, 2 Group B patients
responded to IV VA while the others did not respond
to either drugs. There were no significant differ-
ences among the treatments with respect to recur-
rence during the 12 h study period or the outcome at
7 days. Mortality rate in both the groups was 8% (4/
50 in Group A and 4/50 in Group B) (Table 4). One
(2%) patient in Group A and one (2%) patient in
Group B left the treatment against medical advice
due to the cost of total treatment (Table 4). Mild





Recurrence in 12 h 6* 8 *
Recurrence in 24 h 0 0
Mortality 4 4
Left against medical advice 1 1
* p value > 0.05.cases treated with IV VAwhile 12% (6/50) patients of
Group B developed hypotension and 4% (2/50)
developed respiratory depression (Table 5).Discussion
Both the groups A and B were age and sex matched.
The majority of the patients were of young age in
both groups. In our study IV VA in doses of 20 mg/kg
(Limdi et al.20) as loading dose at rate of 40 mg/min.
The US Food and Drug Administration approved the
IV formulation of valproic acid in 1996, with the
original rate of 20 mg/min.23 Although earlier stu-
dies established the safety of IV administration of
valproate, slow infusion rates limited its use in
emergency situations.24,26 In the past 5 years, sev-
eral studies have demonstrated the safety of rapid
administration (up to 6 mg/kg/min)23—25 of IV VA
loading doses (up to 45 mg/kg)26 and efficacy (ran-
ging from 66% to 100%) in acute repetitive seizures
and SE.24
According to studies from Western countries, the
major etiologies of SE in adults include antiepileptic
noncompliance, ethanol/drug related, metabolic
disorders and anoxia/hypoxia.27—29 However, anti-
epileptic drug withdrawal/noncompliance (26/100,
26%), inflammatory granuloma (24/100, 24%), CNS
infections (22/100, 22%) dominate as the etiological
causes in the current study, underscoring the impor-
tance of infections as one of the major, yet trea-
table, cause of SE in this tropical country.Table 5 Adverse effects of therapy





Respiratory depression 0 2
Mild elevation of SGPT 4 0
Total adverse events 4 * 8 *
* p value > 0.05.
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ered as major etiological factors for epilepsy in
many Indian studies reported earlier.30
In the present study, status epilepticus was inter-
rupted successfully in 88% in Group A and 84% in
Group B ( p > 0.05). It was comparable to the result
of other studies. Czapinski and Terezynski18 in 1998
reported an 80% success rate in interrupting SE in a
series of 20 adult patients using IV valproic acid in a
bolus dose of 15 mg/kg followed by an infusion of
1 mg/kg/h. Peters and Pohlmann-Eden19 have
reported 85.6% success in controlling SE in a series
of 102 adult patients using IV VA.
In our study 40% of Group A and 48% of Group B
were having SE >2 h at the time of presentation,
however, in these cases overt seizure activity had
seized to occur 30 min after the seizure onset
but they failed to regain consciousness at the
time of hospital admission. The duration of SE
was considerably prolonged as compared to other
studies12,28,31 reported from the developed coun-
tries. This delay in presentation might be attributed
to the lack of awareness amongst the general public,
inadequacy of medical and health services in this
part of the world and the ignorance amongst the
treating physicians regarding the need for emer-
gency management of SE. The response to treat-
ment was significantly better in patients having SE
<2 h than SE >2 h in both the groups (p < 0.05).
Limdi et al.20 used IV valproic acid in a series of 63
patients of SE with an average dose of 31.5 mg/kg
and found an overall efficacy of 63.3%. A better
response was achieved in patients in whom SE had
lasted<2 h before treatment. The delayed response
in control of SE was associated with longer duration
between onset of SE to beginning of therapy and
underlying comorbid conditions in patients of SE as
reported in other studies.28,31
In six patients of Group A (IV VA) and eight
patients of Group B (IV phenytoin) recurrence of
seizures was noted within 12 h after successfully
ending the first episode of SE. There was no
significant difference in response to SE after switch-
ing over to other drug in either of the group. Six out
of twelve patients of SE were refractory to both
the drugs suggesting some common mechanism of
antiepileptic drug activity of both the drugs. No
recurrence of seizures was noted within 1 week of
follow-up in either of the groups suggesting no
difference in neurological outcome at discharge in
both groups.
In this study IV VAwas well tolerated in patients of
SE in comparison to IV phenytoin. Mild elevation of
liver enzymes (SGPT) was noted in four cases trea-
ted with IV VA whereas side effects like hypotension
(six cases), respiratory depression (two cases) werenoted in patients who were loaded with IV pheny-
toin. No fall in BP or respiratory depression was
noted in patients treated with IV VA, therefore it
seems to be safe in patients having cardio-respira-
tory disease. There was no significant difference
with respect to total adverse events in the two
groups (p > 0.05). Limdi and Faught32 described
the safety of rapid infusion of valproic acid in doses
ranging from 33.3 to 555 mg/min (median, 200 mg/
min) without serious adverse effects. Venkataraman
and Wheless25 have also shown the safety of rapid
loading doses of IV VA (mean dose 24.2 mg/kg and
target infusion rates 3 or 6 mg/kg/min). Wheless
et al.33 in 2004 demonstrated that IV VA adminis-
tered to patients with epilepsy at rates of infusion of
up to 6 mg/kg/min and doses of up to 30 mg/kg does
not cause clinically significant negative effects on
blood pressure and pulse rate and caused only mild-
to-moderate, reversible adverse events. The data
given by Sinha and Nariotoku34 also demonstrated
that IV VA loading is well tolerated, even in patients
with cardiovascular instability (review of hospital
records of 13 patients with SE and hypotension).
In our study 22 patients were below 18 years of
age in Group A, 20 cases were controlled with IV VA.
In Group B, 16 patients were below 18 years of age
out of which four cases were refractory reflecting no
relation of the response of the drug to the age of the
patient. Two responded to IV VA while the other
patients were refractory to both drugs. Status epi-
lepticus was controlled in 92% (92/100) of patients
in total. Overall mortality was noted in 8% (8/100) of
patients and two patients left against medical
advice in total. These data suggest improvement
from previous studies15,28,31 reflecting improved
care of the patients, change in operating definition
of SE (from >60 min to >10 min and operating
definition of >5 min) and high success with newer
drugs like IV VA. Outcome of SE is determined by
age, duration of status, cause of SE and other
comorbid conditions as reported in other stu-
dies.32,25 Acute processes that cause SE such as
electrolyte abnormalities, renal failure, sepsis,
stroke, head trauma and hypoxia are associated
with high mortality, especially those occurring after
hypoxia and in older patients.Conclusions
In our present study IV VA was found to be as
effective as IV phenytoin, with better tolerability
as compared to IV phenytoin. IV VA can be used to
treat all types of status including myoclonic status,
where, this is the only drug which is effective. IV VA
can be used as first line of treatment of SE after
532 P. Agarwal et al.benzodiazepines as an alternative to phenytoin,
especially in patients of cardio-respiratory disease.
The response to treatment was better in patients of
SE <2 h than >2 h reflecting need of immediate
treatment. The prolonged duration of SE at admis-
sion suggests requirement for increased awareness
of immediate treatment of this fatal neurological
disease among health workers and physicians in this
part of developing world.References
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